利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

4 条记录 (耗时 0.011 秒)

    von Willebrand factor or factor VIII and von Willebrand factor for the treatment of coagulopathy induced by inhibitors of thrombocytes
    1.
    发明授权
    von Willebrand factor or factor VIII and von Willebrand factor for the treatment of coagulopathy induced by inhibitors of thrombocytes 有权
    血管性血友病因子或因子VIII和血管性血友病因子用于治疗由血小板抑制剂诱导的凝血病

    公开(公告)号：US09095564B2

    公开(公告)日：2015-08-04

    申请号：US14071193

    申请日：2013-11-04

    申请人： CSL Behring GmbH

    发明人： Gerhard Dickneite ,  Ingo Pragst ,  Henrique Lessa ,  Thorsten Haas ,  Stefan Zeitler

    IPC分类号： A61K38/37 ,  C07K14/755 ,  A61K38/36

    CPC分类号： A61K38/36 ,  A61K35/13 ,  A61K38/37 ,  A61K2300/00

    摘要： The present invention relates to a von Willebrand Factor for use in the treatment and/or prevention of a bleeding event associated with a thrombopathy induced by substances inhibiting thrombocytes. Furthermore, the present invention relates to a method of treating and/or preventing a disorder related to a bleeding event associated with a thrombopathy induced by substances inhibiting thrombocytes comprising administering a pharmaceutically effective amount of a von-Willebrand-Factor (vWF) to a patient in need thereof. The present invention also relates to a composition comprising vWF and a composition comprising FVIII for simultaneous, separate or sequential use for use in the treatment and/or prevention of a bleeding event associated with a thrombopathy induced by substances inhibiting thrombocytes.

    摘要翻译： 本发明涉及一种用于治疗和/或预防与抑制凝血细胞的物质诱导的血栓形成相关的出血事件的血管性血友病因子。 此外，本发明涉及治疗和/或预防与由抑制凝血细胞的物质引起的血栓形成相关的出血事件相关疾病的方法，其包括向患者施用药学有效量的血管性血友病因子（vWF） 需要它。 本发明还涉及包含vWF的组合物和包含用于同时，分开或顺序使用的FVIII的组合物，其用于治疗和/或预防与抑制凝血细胞的物质诱导的血栓形成相关的出血事件。

    Use of C1-inhibitor for the treatment of secondary edema of the central nervous system
    2.
    发明授权
    Use of C1-inhibitor for the treatment of secondary edema of the central nervous system 有权
    使用C1抑制剂治疗中枢神经系统的继发性水肿

    公开(公告)号：US09452203B2

    公开(公告)日：2016-09-27

    申请号：US14364097

    申请日：2012-12-21

    申请人： CSL BEHRING GMBH

    发明人： Christoph Kleinschnitz ,  Marc Nolte ,  Guido Stoll ,  Gerhard Dickneite ,  Stefan Schulte ,  Bernhard Nieswandt ,  Ingo Pragst

    IPC分类号： A61K38/17 ,  A61K38/57

    CPC分类号： A61K38/57

    摘要： The subject of the present invention is, in the most general aspect, the prevention and/or treatment of a secondary edema. In particular, the present invention relates to a C1-Inhibitor for use in a method of preventing the formation and/or reducing the size of a secondary edema of the central nervous system (CNS) in a subject wherein the subject has or has had at least one disorder selected from the group consisting of stroke, ischemic stroke, hemorrhagic stroke, perinatal stroke, traumatic brain injury and spinal cord injury. Preferably the secondary edema of the CNS is a secondary brain edema. Another subject of the present invention is the treatment of disorders associated with an increased permeability of the blood brain barrier or the blood spinal cord barrier. And a third subject is a plasma-derived C1-inhibitor for use in a method of preventing, reducing or treating brain ischemia-reperfusion injury.

    摘要翻译： 在最一般的方面，本发明的主题是预防和/或治疗二次水肿。 特别地，本发明涉及一种用于防止在受试者中具有或已经具有中枢神经系统（CNS）的中枢神经系统（CNS）的继发性水肿的形成和/或减小的方法的方法的C1抑制剂 选自中风，缺血性中风，出血性中风，围产期中风，创伤性脑损伤和脊髓损伤的至少一种障碍。 优选CNS的继发性水肿是继发性脑水肿。 本发明的另一主题是治疗与血脑屏障或血液脊髓屏障的渗透性增加相关的病症。 并且第三个受试者是用于预防，减少或治疗脑缺血 - 再灌注损伤的方法中的等离子体衍生的C1抑制剂。

    USE OF C1-INHIBITOR FOR THE TREATMENT OF SECONDARY EDEMA OF THE CENTRAL NERVOUS SYSTEM
    4.
    发明申请
    USE OF C1-INHIBITOR FOR THE TREATMENT OF SECONDARY EDEMA OF THE CENTRAL NERVOUS SYSTEM 有权
    C1抑制剂治疗中枢神经系统二次治疗的用途

    公开(公告)号：US20140371425A1

    公开(公告)日：2014-12-18

    申请号：US14364097

    申请日：2012-12-21

    申请人： CSL BEHRING GMBH

    发明人： Christoph Kleinschnitz ,  Marc Nolte ,  Guido Stoll ,  Gerhard Dickneite ,  Stefan Schulte ,  Bernhard Nieswandt ,  Ingo Pragst

    IPC分类号： A61K38/57

    CPC分类号： A61K38/57

    摘要： The subject of the present invention is, in the most general aspect, the prevention and/or treatment of a secondary edema. In particular, the present invention relates to a C1-Inhibitor for use in a method of preventing the formation and/or reducing the size of a secondary edema of the central nervous system (CNS) in a subject wherein the subject has or has had at least one disorder selected from the group consisting of stroke, ischemic stroke, hemorrhagic stroke, perinatal stroke, traumatic brain injury and spinal cord injury. Preferably the secondary edema of the CNS is a secondary brain edema. Another subject of the present invention is the treatment of disorders associated with an increased permeability of the blood brain barrier or the blood spinal cord barrier. And a third subject is a plasma-derived C1-inhibitor for use in a method of preventing, reducing or treating brain ischemia-reperfusion injury.

    摘要翻译： 在最一般的方面，本发明的主题是预防和/或治疗二次水肿。 特别地，本发明涉及一种用于防止在受试者中具有或已经具有中枢神经系统（CNS）的中枢神经系统（CNS）的继发性水肿的形成和/或减小的方法的方法的C1抑制剂 选自中风，缺血性中风，出血性中风，围产期中风，创伤性脑损伤和脊髓损伤的至少一种障碍。 优选CNS的继发性水肿是继发性脑水肿。 本发明的另一主题是治疗与血脑屏障或血液脊髓屏障的渗透性增加相关的病症。 并且第三个受试者是用于预防，减少或治疗脑缺血 - 再灌注损伤的方法中的等离子体衍生的C1抑制剂。